湖北亨迪药业股份有限公司 董事会薪酬与考核委员会工作细则 湖北亨迪药业股份有限公司 董事会薪酬与考核委员会工作细则 （2025 年 12 月） 第一章 总则 第一条 为进一步建立健全公司董事及高级管理人员的考核和薪酬管理制度， 完善公司治理结构，根据《中华人民共和国公司法》和《公司章程》，参照《上市 公司治理准则》及其他有关规定，公司特设立董事会薪酬与考核委员会，并制定本 工作细则。 第二条 薪酬与考核委员会是董事会设立的专门工作机构，对董事会负责，主 要负责制定公司董事及高级管理人员的考核标准并进行考核，制定、审查公司董事 及高级管理人员的薪酬政策与方案。 第三条 本细则所称董事是指在本公司支取薪酬的董事长、董事，高级管理人 员是指董事会聘任的经理、副经理、董事会秘书、财务负责人及《公司章程》规定 的其他高级管理人员。 第二章 人员组成 第四条 薪酬与考核委员会由三名董事组成，独立董事应当过半数。 第五条 薪酬与考核委员会委员应由董事长、二分之一以上独立董事或全体董 事三分之一以上提名，并由董事会选举产生。 第六条 薪酬与考核委员会委员应具备以下条件： （一）熟悉国家有关法律、行政法规，具有薪酬与考核方面的 ...

湖北亨迪药业股份有限公司 董事、高级管理人员薪酬管理制度 （2025 年 12 月） 第一章 总则 第一条 为完善湖北亨迪药业股份有限公司（以下简称"公司"）董事、高 级管理人员的薪酬管理，建立科学有效的激励与约束机制，有效调动公司董事、 高级管理人员的工作积极性，提高公司的经营管理效益，促进公司健康、持续、 稳定发展，根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公 司治理准则》等有关法律、法规、规范性文件，以及《湖北亨迪药业股份有限公 司章程》（以下简称"《公司章程》"）的有关规定，特制定本制度。 第二条 本制度所称董事、高级管理人员是指由股东会或董事会批准任命的 全体董事、总经理、副总经理、董事会秘书、财务总监和《公司章程》规定的其 他高级管理人员。 第三条 公司高级管理人员薪酬管理制度遵循以下原则： （一）坚持薪酬与公司长远发展和利益相结合原则； （二）坚持按劳分配与责、权、利相结合的原则； （三）坚持总体薪酬水平与公司实际经营情况相结合的原则； 湖北亨迪药业股份有限公司 董事、高级管理人员薪酬管理制度 （四）坚持薪酬与年度绩效考核相匹配的原则； （五）坚持激励与约束并重的原则。 第二章 ...

Group 1 - The core viewpoint of the news is that Hendi Pharmaceutical experienced a decline in stock price and trading volume, with significant changes in financing and stockholder metrics [1][2]. Group 2 - On December 23, Hendi Pharmaceutical's stock fell by 2.35%, with a trading volume of 88.08 million yuan. The financing buy-in amount was 7.56 million yuan, while the financing repayment was 6.23 million yuan, resulting in a net financing buy of 1.33 million yuan [1]. - As of December 23, the total financing and securities lending balance for Hendi Pharmaceutical was 124 million yuan, which is 2.39% of its circulating market value, indicating a low financing balance compared to the past year [1]. - In terms of securities lending, on December 23, Hendi Pharmaceutical repaid 900 shares and sold 900 shares, with a selling amount of 11,200 yuan. The remaining securities lending volume was 22,300 shares, with a balance of 277,400 yuan, which is at a high level compared to the past year [1]. Group 3 - As of December 19, the number of shareholders for Hendi Pharmaceutical was 21,400, a decrease of 3.15%, while the average circulating shares per person increased by 3.25% to 19,531 shares [2]. - For the period from January to September 2025, Hendi Pharmaceutical reported an operating income of 319 million yuan, a year-on-year decrease of 4.52%, and a net profit attributable to shareholders of 20.93 million yuan, down 71.96% year-on-year [2]. - Since its A-share listing, Hendi Pharmaceutical has distributed a total of 378 million yuan in dividends, with 306 million yuan distributed over the past three years [2].

证券日报网讯12月23日，亨迪药业（301211）在互动平台回答投资者提问时表示，截至2025年12月19 日，公司股东户数为21381户。 ...

证券日报网讯12月15日，亨迪药业（301211）在互动平台回答投资者提问时表示，截至2025年12月10 日，公司股东户数为22076户。 ...

亨迪药业12月15日披露，截至12月10日公司股东户数为22076户，较上期（11月30日）减少2079户，环 比降幅为8.61%。 证券时报·数据宝统计，截至发稿，亨迪药业最新股价为12.74元，下跌0.39%，本期筹码集中以来股价 累计下跌16.13%。具体到各交易日，1次上涨，10次下跌。 公司发布的三季报数据显示，前三季公司共实现营业收入3.19亿元，同比下降4.52%，实现净利润 2093.34万元，同比下降71.96%，基本每股收益为0.0500元，加权平均净资产收益率0.92%。（数据宝） （文章来源：证券时报网） ...

Group 1 - The core point of the news is that Hendi Pharmaceutical executed a block trade of 162,800 shares on December 2, with a transaction value of 2.0138 million yuan, representing 1.16% of the total trading volume for that day [1] - The transaction price was 12.37 yuan, which is a discount of 16.14% compared to the market closing price of 14.75 yuan [1] - The buyer was a branch of Founder Securities Co., Ltd., while the seller was a branch of Guotai Junan Securities Co., Ltd. [2]

Group 1 - The core point of the article is that Hendi Pharmaceutical (301211) reported a total of 24,155 shareholders as of November 28, 2025 [1]

Group 1 - The flu-related concept has become active again, with Haiwang Bio hitting the daily limit up [2] - Yue Wannianqing has increased by over 12% [2] - Other companies such as Guangji Pharmaceutical, Hendi Pharmaceutical, Te Yi Pharmaceutical, Jinshi Yiyao, and Xinhua Pharmaceutical have also seen gains [2]

Group 1 - The hepatitis concept sector declined by 0.31%, ranking among the top declines in concept sectors, with companies like Zhongsheng Pharmaceutical and Guangji Pharmaceutical hitting the limit down [1][2] - Major stocks in the hepatitis sector that saw significant outflows include Zhongsheng Pharmaceutical with a net outflow of 684 million yuan, followed by Te Yi Pharmaceutical and Pian Zai Huang with net outflows of 112 million yuan and 81 million yuan respectively [2][3] - Conversely, stocks that experienced net inflows include Baihua Pharmaceutical, Huadong Medicine, and Kangzhi Pharmaceutical, with inflows of 97.75 million yuan, 43.11 million yuan, and 21.20 million yuan respectively [6] Group 2 - The top gainers in the hepatitis sector included Baihua Pharmaceutical, which rose by 10.01%, followed by Chengda Pharmaceutical and Kangzhi Pharmaceutical with increases of 4.79% and 3.00% respectively [1][6] - The overall market sentiment for the hepatitis sector appears negative, as evidenced by the significant net outflows and the number of stocks declining in value [2][3] - The trading volume for Zhongsheng Pharmaceutical was notably high, with a turnover rate of 18.78%, indicating active trading despite the price drop [2][3]